Zelira Therapeutics Ltd.ASX: ZLD

Quarterly Activities/Appendix 4C Cash Flow Report

· Issued by Zelira Therapeutics Ltd. via ASX

Filed with ASX ·

30 July 2026 Key Highlights Transformative US$33M Fundraising into Zelira’s HOPE® 1 SPV • Zelira’s HOPE ® 1 SPV signed definitive agreements to raise US$32,981,075 (before costs), announced 16 January • On a fully diluted basis Zelira retains 39.70% interest in the HOPE ® 1...

View Attachment

6ix hasn’t read this filing yet.

Zelira Therapeutics Ltd. on 6ix

Story so far

Earlier from Zelira Therapeutics

Later from Zelira Therapeutics

All Zelira Therapeutics news releases